Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vibrio cholerae Ogawa 50 classical biotype, heat inactivated
- Development stage
- Phase 1
- Lead developer
- EuBiologics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Vibrio cholerae Ogawa 50 classical biotype, heat inactivated is a component of several oral whole-cell killed (WCK) cholera vaccines. It consists of the O1 Ogawa serotype of Vibrio cholerae (Cairo 50 strain), which has been rendered non-infectious by heat inactivation. This antigen is used as part of multivalent oral vaccines such as Euvichol and Dukoral for the prevention of cholera. The mechanism involves induction of mucosal and systemic immunity against *V. cholerae* O1 antigens to prevent colonization and toxin-mediated disease following exposure[5][7][8]. These vaccines are primarily indicated for prophylaxis against infection with *Vibrio cholerae* O1 strains.
- Brand names
- euvichol
- Other names
- v. cholerae o1 ogawa cairo 50 classical biotype, heat inactivated
02
Targets
O1 Ogawa antigen (Vibrio cholerae O1 Ogawa antigen)
Beyond the preview
Go deeper on Vibrio cholerae Ogawa 50 classical biotype, heat inactivated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vibrio cholerae Ogawa 50 classical biotype, heat inactivated.